Adstiladrin...In Dec,2022 Adstiladrin was approved by the FDA for bladder cancer.
Adstiladrin is not a definitive cure, the purpose of Adstiladrin is for decreasing the risk of recurence and progression for BCG-Unresponsive NMIBC patients.
Patients who are immuno-deficient can't be treated with Adstiladrin.
Note: This is a big restriction as older patients are more likely to be immuno-deficient.
-TLD-1433 will have no problems treating patients that are immuno-deficients.
The FDA gave Adstiladrin "Priority Review, Breakthrough Therapy and Fast Track Designation".
The above is just to show that the FDA is willing to speed up the processing of any treatment that could help BCG-Unresponsive NMIBC patients.
If the FDA is willing to give Breakthrough Therapy, to a treatment that doesn't even cure Bladder cancer(Adstiladrin)...TLD-1433 is definitively a good candidate for BTD.
In short...TLD-1433 is far more superior to any treatments already approved by the FDA for BCG-resistant NMIBC(Keytruda,Adstiladrin).
-Another big advantage is that unlike BCG, TLD-1433 is very easy to produce in big quantity(no shortage).
I love my TLT shares.